RxDoctor Payments Data

Jason Guillot, MD

Otolaryngology/Facial Plastic Surgery · Mandeville, LANPI 1912126723

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,000 of the $12,750 with a category attached, or 86.3%. Aerin Medical Inc. accounts for 86.8% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $11,240, more than ten times the $741 reported in 2019.

$12,750in general payments, 2019–2025

Across 88 payments — averaging $144.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerin Medical Inc.$11K
  • Acclarent, Inc$293
  • GSK$228
  • Sanofi$169
  • Arrinex, Inc.$160
  • Optinose US, Inc.$139
  • plus $695 from 15 others

What the payments were for

  • Consulting fees$11,00086%
  • Food & beverage$1,71613%
  • Education$340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few otolaryngology/facial plastic surgery providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$408,517
Medicare patients
600
Services billed
8,667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab13$46,970
Azelastine Hcl174$4,591
Fluticasone Propionate269$3,800
Epinephrine13$2,173
Ipratropium Bromide87$2,098
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth19$2,041
Wixela InhubFluticasone Propion/Salmeterol24$1,842
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$1,770
Fluocinolone Acetonide Oil39$1,522
Mupirocin40$1,329
Dexamethasone39$1,132
Ofloxacin42$1,042
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen94$893
Cephalexin96$678
Methylprednisolone106$644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$23$2,17313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few otolaryngology/facial plastic surgery providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other otolaryngology/facial plastic surgery in Mandeville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →